OLBA HEALTHCARE (2689) investor relations material

Executive summary

• Q1 FY2027 net sales rose 2.0% YoY to ¥31,454 million, while operating profit fell 45.5% to ¥141 million and profit attributable to owners of parent fell 77.9% to ¥36 million.

• Results cover the three months ended September 30, 2026; two companies were newly included in the consolidation scope.

Financial highlights

• Net sales were ¥31,454.542 million versus ¥30,824.228 million YoY; gross profit was ¥3,480.661 million versus ¥3,375.529 million.

• Operating profit was ¥141.140 million versus ¥258.791 million YoY; ordinary profit was ¥122.330 million versus ¥255.982 million.

• Profit attributable to owners of parent was ¥36.841 million versus ¥166.754 million; comprehensive income was ¥22.279 million versus ¥138.478 million.

• Total assets were ¥74,152 million at September 30, 2026, versus ¥46,653 million at June 30; net assets were ¥20,844 million versus ¥13,061 million.

Outlook and guidance

• FY2027 forecast: net sales ¥178,885 million (+41.3% YoY), operating profit ¥1,986 million (+18.3%), ordinary profit ¥1,950 million (+17.2%), and parent-attributable profit ¥1,172 million (+5.4%).

• FY2027 forecast basic EPS is ¥130.30; six-month forecast net sales are ¥80,285 million and parent-attributable profit is ¥355 million.

• Financial result and cash dividend forecasts were revised on October 30, 2026; the FY2027 annual dividend forecast is ¥80 per share.